UK antibody developer F-star Therapeutics has become a private, independent biotech. The surprise move - announced via F-star's LinkedIn page on Thursday - comes two years after a drawn-out $161 million M&A exit ...
F-star is an England-based biotechnology company that develops and commercializes novel antibody therapies for the treatment of cancer and orphan diseases.